Genomic tests to guide prostate cancer management following diagnosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Molecular Diagnostics

• Publication date

  2017-03-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14737159.2017.1302332PMID 28277880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

  2017influential reference
• Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential

  2017cited by this paper
• DNA Repair in Prostate Cancer: Biology and Clinical Implications.

  2017cited by this paper
• Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

  2016cited by this paper
• Prostate Cancer: Localized: Radiation TherapyMP14-12 EFFICACY OF EARLY AND DELAYED RADIATION IN A PROSTATECTOMY COHORT ADJUSTED FOR GENOMIC AND CLINICAL RISK

  2016cited by this paper
• Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.

  2016cited by this paper
• Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.

  2016cited by this paper
• 435 Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk

  2016cited by this paper
• Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.

  2016cited by this paper
• Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk.

  2016cited by this paper
• Prostate Cancer, Version 1.2016.

  2016influential reference
• Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy

  2016cited by this paper
• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration‑Resistant Prostate Cancer

  2016cited by this paper
• Clinical Utility of Biomarkers in Localized Prostate Cancer

  2016cited by this paper
• Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.

  2016influential reference
• COSMIC: High‐Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer

  2016cited by this paper
• PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

  2016cited by this paper
• New treatment options in castration-resistant prostate cancer.

  2015influential reference
• A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

  2015cited by this paper
• Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

  2015cited by this paper
• Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy

  2015cited by this paper
• A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

  2015cited by this paper
• Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence

  2015cited by this paper
• PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer

  2015cited by this paper
• Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

  2015cited by this paper
• Spatial genomic heterogeneity within localized, multifocal prostate cancer

  2015cited by this paper
• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

  2015cited by this paper
• Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer

  2015cited by this paper
• Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

  2015cited by this paper
• Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

  2015cited by this paper
• Docetaxel and Prednisone with or without Lenalidomide in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer ( MAINSAIL ) : A Randomised , Double-Blind , Placebo-Controlled Phase 3 Trial

  2015cited by this paper
• A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

  2015cited by this paper
• Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error

  2014cited by this paper
• Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.

  2014cited by this paper
• Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy

  2014influential reference
• European perspective for effective cancer drug development

  2014cited by this paper
• A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

  2014cited by this paper
• PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy

  2014cited by this paper
• PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

  2014cited by this paper
• Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

  2014cited by this paper
• Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014cited by this paper
• A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy

  2013cited by this paper
• Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

  2013cited by this paper
• Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy

  2013cited by this paper
• Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies

  2013cited by this paper
• Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort

  2013cited by this paper
• Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

  2013cited by this paper
• Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer

  2013cited by this paper
• Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.

  2013cited by this paper
• Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

  2013cited by this paper
• Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

  2013cited by this paper
• Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

  2013cited by this paper
• Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

  2013cited by this paper
• Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

  2013cited by this paper
• Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

  2012cited by this paper
• Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

  2012cited by this paper
• Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

  2011cited by this paper
• PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

  2011cited by this paper
• Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

  2011cited by this paper
• Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

  2009cited by this paper
• Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance

  2009cited by this paper
• Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy

  2009cited by this paper
• Is PTEN loss associated with clinical outcome measures in human prostate cancer?

  2008cited by this paper
• Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

  2008cited by this paper
• Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

  2008cited by this paper
• Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.

  2006cited by this paper
• Concordance among gene-expression-based predictors for breast cancer.

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2005cited by this paper
• Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.

  2005cited by this paper
• Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

  2004cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Identification of genes periodically expressed in the human cell cycle and their expression in tumors.

  2002cited by this paper
• PTEN/MMAC1/TEP1 involvement in primary prostate cancers

  1998cited by this paper
• Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

  1998cited by this paper
• Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.

  1998cited by this paper
• Analysis of PTEN and the 10q23 region in primary prostate carcinomas

  1998cited by this paper
• Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

  1997cited by this paper
• Heterogeneity of prostate cancer in radical prostatectomy specimens.

  1994cited by this paper
• Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

  1984cited by this paper
• Urological Survey Urological Oncology : Prostate Cancer Re : Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort

  year unknowncited by this paper

• Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer

  2023cites this paper
• Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.

  2022cites this paper
• Nomograms in Urologic Oncology: Lights and Shadows

  2021cites this paper
• Prostate cancer: more effective use of underutilized postoperative radiation therapy

  2020cites this paper
• microRNA-1271 impedes the development of prostate cancer by downregulating PES1 and upregulating ERβ

  2020cites this paper
• Neoplasms of the Prostate

  2020cites this paper
• Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy

  2019cites this paper
• Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.

  2019cites this paper
• Identificación de biomarcadores predictivos, pronósticos y de respuesta al tratamiento en cáncer de próstata

  2018cites this paper
• Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.

  2017cites this paper
• Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness

  2017cites this paper